These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1003 related articles for article (PubMed ID: 27704396)
1. Advanced Glycation End Products, Diabetes, and Bone Strength. Yamamoto M; Sugimoto T Curr Osteoporos Rep; 2016 Dec; 14(6):320-326. PubMed ID: 27704396 [TBL] [Abstract][Full Text] [Related]
2. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Yamagishi S Curr Drug Targets; 2011 Dec; 12(14):2096-102. PubMed ID: 22023404 [TBL] [Abstract][Full Text] [Related]
3. Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties. Karim L; Bouxsein ML Bone; 2016 Jan; 82():21-7. PubMed ID: 26211993 [TBL] [Abstract][Full Text] [Related]
4. Advanced Glycation End Products, Bone Health, and Diabetes Mellitus. Jiang J; Zhao C; Han T; Shan H; Cui G; Li S; Xie Z; Wang J Exp Clin Endocrinol Diabetes; 2022 Oct; 130(10):671-677. PubMed ID: 36257297 [TBL] [Abstract][Full Text] [Related]
5. Non-invasive skin autofluorescence, blood and urine assays of the advanced glycation end product (AGE) pentosidine as an indirect indicator of AGE content in human bone. Kida Y; Saito M; Shinohara A; Soshi S; Marumo K BMC Musculoskelet Disord; 2019 Dec; 20(1):627. PubMed ID: 31881872 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease. Prasad K; Tiwari S Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648 [TBL] [Abstract][Full Text] [Related]
7. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions. Neviere R; Yu Y; Wang L; Tessier F; Boulanger E Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623 [TBL] [Abstract][Full Text] [Related]
8. Ratio of Endogenous Secretory Receptor for Advanced Glycation End Products to Pentosidine Predicts Fractures in Men. Tamaki J; Kouda K; Fujita Y; Iki M; Yura A; Miura M; Sato Y; Okamoto N; Kurumatani N J Clin Endocrinol Metab; 2018 Jan; 103(1):85-94. PubMed ID: 29040721 [TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Valencia JV; Weldon SC; Quinn D; Kiers GH; DeGroot J; TeKoppele JM; Hughes TE Anal Biochem; 2004 Jan; 324(1):68-78. PubMed ID: 14654047 [TBL] [Abstract][Full Text] [Related]
10. Role of Advanced Glycation Endproduct (AGE)-Receptor for Advanced Glycation Endproduct (RAGE) Axis in Cardiovascular Disease and Its Therapeutic Intervention. Yamagishi SI Circ J; 2019 Aug; 83(9):1822-1828. PubMed ID: 31366777 [TBL] [Abstract][Full Text] [Related]
11. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Khalid M; Petroianu G; Adem A Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454131 [TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease. Reynaert NL; Gopal P; Rutten EPA; Wouters EFM; Schalkwijk CG Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):403-418. PubMed ID: 27373680 [TBL] [Abstract][Full Text] [Related]
13. The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions. Hamada Y; Kitazawa S; Kitazawa R; Kono K; Goto S; Komaba H; Fujii H; Yamamoto Y; Yamamoto H; Usami M; Fukagawa M Endocrine; 2010 Dec; 38(3):369-76. PubMed ID: 20972729 [TBL] [Abstract][Full Text] [Related]
14. Activation of the receptor for advanced glycation end products and consequences on health. Wautier MP; Guillausseau PJ; Wautier JL Diabetes Metab Syndr; 2017; 11(4):305-309. PubMed ID: 27612394 [TBL] [Abstract][Full Text] [Related]
15. Activation of RAGE-dependent endoplasmic reticulum stress associates with exacerbated postmyocardial infarction ventricular arrhythmias in diabetes. Liu Z; Zhang Y; Pan S; Qiu C; Jia H; Wang Y; Zhu H Am J Physiol Endocrinol Metab; 2021 Mar; 320(3):E539-E550. PubMed ID: 33459180 [TBL] [Abstract][Full Text] [Related]
16. Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation. Zhang H; Chu Y; Zheng H; Wang J; Song B; Sun Y Aging (Albany NY); 2020 Nov; 13(1):525-536. PubMed ID: 33298623 [TBL] [Abstract][Full Text] [Related]
17. Advanced glycation and glycoxidation end products in bone. Wang B; Vashishth D Bone; 2023 Nov; 176():116880. PubMed ID: 37579812 [TBL] [Abstract][Full Text] [Related]
18. Advanced Glycation End Products: Do They Impair Bone Health in Diabetes? Papachristou S; Rizzo M; Papanas N Exp Clin Endocrinol Diabetes; 2022 Oct; 130(10):636-637. PubMed ID: 35977693 [TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products and insulin resistance. Unoki H; Yamagishi S Curr Pharm Des; 2008; 14(10):987-9. PubMed ID: 18473850 [TBL] [Abstract][Full Text] [Related]
20. Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men. Lamb LS; Alfonso H; Norman PE; Davis TME; Forbes J; Müench G; Irrgang F; Almeida OP; Golledge J; Hankey GJ; Flicker L; Yeap BB J Clin Endocrinol Metab; 2018 Nov; 103(11):4224-4231. PubMed ID: 30137355 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]